Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
PASADENA, Calif.--( BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results.
We had another quarter of strong execution across all areas of our business and we think Arrowhead is extremely well positioned to build on this progress throughout 2026 and beyond.
“We had another quarter of strong execution across all areas of our business and we think Arrowhead is extremely well positioned to build on this progress throughout 2026 and beyond,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “In fact, the recent months have included some of the more significant achievements in our Company’s history. We received regulatory approval for REDEMPLO® in familial chylomicronemia syndrome in three different countries and launched our first commercial product in the U.S.; we continued to grow our cardiometabolic portfolio; we had encouraging early results from our obesity programs; we advanced our TRiM™ platform and CNS pipeline; and, lastly, we meaningfully improved our financial position to advance these and other programs forward.”
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BIf75928b390fb452f963ab43a18d60220. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
Key Commercial Events
Key R&D Events
Key Corporate Events
Selected Fiscal 2026 First Quarter Financial Results
ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED CONDENSED FINANCIAL INFORMATION
(in thousands, except per share amounts)
Three months Ended December 31,
OPERATING SUMMARY
2025
2024
Revenue
$
264,033
$
2,500
Operating Expenses:
Research and development
177,203
137,002
General and administrative expenses
46,021
26,910
Total operating expenses
223,224
163,912
Operating income (loss)
40,809
(161,412
)
Total other expense
(12,538
)
(13,703
)
Income (loss) before income tax expense and noncontrolling interest
28,271
(175,115
)
Income tax expense
29
103
Net income (loss) including noncontrolling interest
28,242
(175,218
)
Net loss attributable to noncontrolling interest, net of tax
(2,569
)
(2,133
)
Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.
$
30,811
$
(173,085
)
Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted
$
0.22
$
(1.39
)
Weighted-average shares used in calculating - Diluted
140,706
124,848
December 31,
2025
September 30,
2025
FINANCIAL POSITION SUMMARY
(unaudited)
Cash, cash equivalents and restricted cash
$
201,642
$
226,548
Available-for-sale securities, at fair value and short-term investments
714,967
692,818
Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value and short-term investments)
916,609
919,366
Other current and long-term assets
687,572
465,929
Total Assets
$
1,604,181
$
1,385,295
Liability related to the sale of future royalties
$
374,997
$
367,397
Credit Facility
203,108
254,883
Deferred revenue
165,758
2,399
Other liabilities
297,621
257,200
Total Liabilities
$
1,041,484
$
881,879
Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity
568,422
466,052
Noncontrolling Interest
(5,725
)
37,364
Total Noncontrolling Interest and Stockholders' Equity
$
562,697
$
503,416
Total Liabilities, Noncontrolling Interest and Stockholders' Equity
$
1,604,181
$
1,385,295
Shares Outstanding
137,391
135,702
About REDEMPLO ® (plozasiran)
REDEMPLO (plozasiran) is approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome (FCS). REDEMPLO is an siRNA therapeutic designed to suppress the production of apoC-III, a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting apoC-III with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is the first and only siRNA FDA-approved treatment studied in both genetically confirmed and clinically diagnosed patients living with FCS.
For more information about REDEMPLO, visit Our Medicines.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
None.
ADVERSE REACTIONS
Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patients treated with REDEMPLO and >5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.
Please see full Prescribing Information for REDEMPLO ®.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts of REDEMPLO (plozasiran) on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates; and our believes and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.